Long Island City, NY, United States of America

Farzin Haque

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2022

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Farzin Haque

Introduction

Farzin Haque is a notable inventor based in Long Island City, NY, with a focus on developing advanced RNA-based therapies. He holds three patents that showcase his commitment to addressing critical health challenges, particularly in cancer treatment.

Latest Patents

Haque's latest patents include groundbreaking work on RNA nanoparticles for brain tumor treatment. This invention involves an artificial RNA nanostructure designed to target brain tumors effectively. The composition includes a multiple branched RNA nanoparticle, a brain tumor targeting module, and a therapeutic agent. Additionally, he has developed a patent related to miRNA for the treatment of breast cancer. This RNA-based composition also features a multiple branched RNA nanoparticle and a breast cancer targeting module, aimed at providing effective treatment for individuals at risk of breast cancer.

Career Highlights

Farzin Haque is affiliated with the University of Kentucky Research Foundation, where he contributes to innovative research in the field of nanomedicine. His work is pivotal in advancing therapeutic strategies that leverage RNA technology to combat cancer.

Collaborations

Haque collaborates with esteemed colleagues such as Peixuan Guo and Hui Li, who share his vision of utilizing RNA nanotechnology for medical advancements.

Conclusion

Farzin Haque's contributions to RNA-based therapies exemplify the potential of innovative research in transforming cancer treatment. His patents reflect a dedication to improving patient outcomes through cutting-edge technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…